In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Latest From C.R. Bard

Samsung Bioepis Aims To Compete On Higher-Strength Humira In US

Samsung Bioepis and Organon have revealed plans to compete with higher-concentration formulations of adalimumab in the US, after the FDA accepted for review an sBLA for a citrate-free 100mg/ml version of the SB5 Hadlima biosimilar that is already approved in a 50mg/ml formulation.

Biosimilars Strategy

Investment Set To Rise, Non-COVID R&D To Normalize As Korean Pharma Looks Ahead To 2022

Scrip takes a look back at the milestone events in the South Korean pharma and biotech industry in 2021 and ahead at what's in store for the coming year, which has kicked off with speculation around a major potential M&A deal.

South Korea Outlook 2022

Samsung Bioepis Celebrates Soliris Success

Samsung Bioepis has revealed positive Phase I trial results for its SB12 proposed eculizumab biosimilar rival to Soliris.

Biosimilars Clinical Trials

How Samsung Bioepis Is Laying A Path For Ophthalmic Biosimilars

With the first approved rival to Lucentis in both the EU and US, Samsung Bioepis is laying the groundwork for biosimilars to break into ophthalmology ahead of launching its Byooviz version of ranibizumab, explains vice-president of commercial strategy Josh Lee.

Biosimilars Strategy
See All

Company Information

  • Industry
  • Medical Devices
  • Other Names / Subsidiaries
    • Davol, Inc.
    • Embo Medical Limited
    • Liberator Medical, Inc.
    • Lutonix, Inc.
    • Medafor, Inc.
    • Medicon, Inc.
    • Neomend, Inc.
    • Rochester Medical, Inc.
    • Vascular Pathways, Inc.
    • FlowCardia, Inc.
    • Bridger Biomed, Inc.
UsernamePublicRestriction

Register